Interim Report January - September 2007

Interim Report January - September 2007

KEY EVENTS DURING THE PERIOD
- Net revenues amounted to MSEK 21.7 (80.3)
- The loss after tax was MSEK 128.6 (loss: 20.5)
- Earnings per share amounted to a loss of SEK 9.24 (loss: 1.54) 
- Orexo establishes a sales force in the Nordic markets by forming a joint
venture with ProStrakan
- The EU registration process of Rapinyl® has been referred to EMEA's Committee
for Medicinal Products for Human Use (CHMP)

THIRD QUARTER 2007
- Net revenues amounted to MSEK 6.5 (24.9)
- The loss after tax was MSEK 34.1 (loss: 11.2)
- Earnings per share amounted to a loss per share was SEK 2.44 (loss: 0.84) 
KEY EVENTS AFTER THE PERIOD
- Orexo enters agreement to acquire Biolipox - first step in creating innovative
specialty pharma company
- Orexo to convene Extraordinary General Meeting on November 1, 2007
- Orexo reports positive results in comparative clinical Phase III trials for
Sublinox™ (OX22)
- Orexo commences phase 1 trials for its incontinence treatment
- Orexo broadens its portfolio in pain relief - commences two new development
projects 



For report in full format, see enclosed link to pdf. 

For more information, please contact 
Zsolt Lavotha, President & CEO, 
+46 (0)18-780 88 12, e-mail: zsolt.lavotha@orexo.se 

Claes Wenthzel, Executive Vice President and CFO, Orexo AB 
+46 (0)18-780 88 44, e-mail: claes.wenthzel@orexo.se

About Orexo 
Orexo is a pharmaceutical company which focuses on identifying suboptimal
therapeutic characteristics of existing products and developing more efficient
and effective delivery methods for them. By combining approved active substances
with Orexo's drug delivery technologies it is possible to significantly enhance
their therapeutic value, such as providing quicker onset of action or ease of
administration. This business model is aimed at bringing products to market
faster with lower development risk and costs. 

Orexo, which has its global headquarters and development laboratories in Sweden,
currently operates across the world through development, licensing and
distribution agreements in all major markets.

Orexo has a balanced portfolio with two products on the market, three in
registration and/or late stage clinical phase, one in clinical phase I, one in
formulation phase and two in early development phase. 

Orexo is listed on the OMX Nordic List Mid Cap (ticker;ORX).
www.orexo.com